Dandelion Science is pioneering the development of the world's first Generative Neuromodulation™ platform, aimed at treating brain disorders by programming network dynamics within the brain. This innovative approach seeks to overcome the limitations of traditional neurochemical treatments, which often have broad and potentially harmful effects on neurofunction. By leveraging advanced technologies, Dandelion aims to enhance drug development in neurology and psychiatry, leading to more precise therapeutic outcomes. Their collaboration with the Swiss Federal Institute of Technology (EPFL) focuses on integrating cutting-edge neuroimaging systems to deepen the understanding of brain function and dysfunction.

The company's Programmable Therapeutics™ platform is positioned to significantly impact the $105 billion pharmaceutical brain health industry. Dandelion's mission is to improve the lives of individuals affected by brain disorders by combining generative technology solutions with rigorous scientific research. Their partnership with leading neuroscientists, such as Professor Dimitri Van De Ville from EPFL, aims to explore the complexities of brain coding and develop non-invasive therapies. This collaboration is expected to yield monumental advancements in neuroscience, enabling a more nuanced understanding of brain processes and the development of targeted treatments.

United States

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Dandelion Science

Company Details